



NZX/ASX Announcement

16 April 2026

TruScreen Submits Three Proposals to UNITAID's Global Cervical Cancer Elimination Call

Highlights

- TruScreen has submitted three proposals for screening programmes across 14 high-burden countries in Africa, Asia-Pacific, and Latin America – addressable market 1Bn women
- The programmes seek to achieve WHO's 90-70-90 milestones over a 36 month period to December 2030
- Funding for these programmes will be up to US\$57.3 million over the three-year period with potential revenue as a consortium lead for TruScreen of up to US\$18.4 million
- Following TruScreen's success with the National Aids Council programme in Zimbabwe, Truscreen has been approached by global aid agencies to submit applications to assist in the achievement of WHO's cervical cancer elimination goals.
- TruScreen has partnered with a number of significant global implementation partners to deliver programme requirements
- Successful applicants for these programmes will be advised on or around November 2026

Truscreen Group Limited (NZX/ASX: TRU) (TruScreen or Company) is pleased to advise that it has submitted three proposals developed in partnership with leading global and regional health organisations, to present a comprehensive programme to deploy TruScreen's portable AI-enabled opto-electronic cervical screening technology across 14 high-burden countries in Africa, Asia-Pacific, and Latin America with an addressable market of one billion women of screening age.

With the approaching deadline to achieve the **90-70-90** milestones by December 2030, member nations of the World Health Organisation (WHO) are implementing programmes to achieve those goals (*90% of girls to be vaccinated for HPV, 70% of woman screened, and 90% of women tested positive to be treated*). The three formal proposals were in response to global funder UNITAID's Call for Proposals: *Accelerating Cervical Cancer Elimination through Secondary Prevention in Low and Middle Income Countries*. UNITAID's Call sought catalytic investments in next-generation diagnostics, digital health, and integrated delivery models to close the persistent gap between screening coverage.

Proposal 1: TruScreen SSA (Sub Saharan Africa) Scale-Up

This complementary proposal is a 36-month scale-up of TruScreen as a standalone AI-enabled screening tool across six African countries, Zimbabwe, South Africa, Eswatini, Rwanda, Nigeria, and Kenya, deploying 270 TruScreen devices across 120+ health facilities and training 500+ health workers and 500,000 women to be screened over 36 months. The programme targets women in decentralized, peri-urban and rural primary care settings, populations that have never accessed any form of cervical screening.

TruScreen's real-time results, point-of-care device requiring no laboratory, pathologist, or cold chain and nurse-led operation make it directly suited to these settings. TruScreen is uniquely suited to the structural constraints that have kept screening coverage below 25% across low and middle income settings.



In Zimbabwe alone, 30,000+ women have been screened with TruScreen devices since 2022 under a partnership with the National AIDS Council. The programme may also unlock UNFPA, UNICEF, and other Global funding pathways for future funding beyond the grant.

Key partners are the National AIDS Council Zimbabwe, PATH, Solina Centre for International Development and Research SCIDaR, RedAid Nigeria, Baylor Foundation Eswatini, and national Ministries of Health across all six countries. See below for details of partners.

Of the US\$15.3M total budget, TruScreen share of funding would be US\$3.34M as consortium lead.

Proposal 2: African Screen-and-Treat Programme

This transformative proposal introduces same-visit screen-and-treat model across the same six African countries with the highest-burden cervical cancer countries globally. This proposal will screen 400,000 women and treat up to 90% of those eligible.

Patients will receive a HPV rapid testing and also a TruScreen examination, followed by immediate treatment all in a single clinic visit. Evidence from the landmark China's Chinese Obstetricians and Gynecologists Association (COGA) multicenter study (14,982 women, 64 hospitals) confirms this dual approach has the best performance and catches the most number of cancers. The screen-and-treat protocol is critical to eliminate the time gap between diagnosis and care. This will dramatically increase treatment uptake and ensure that a positive result translates directly into a health outcome, not a referral that may never be acted upon.

With a total budget of US\$19.5M, TruScreen share of funding would be US\$5.85M as lead organization.

Proposal 3: Asia-Pacific & Latin America Scale up

This proposal addresses the cervical cancer crisis across eight countries in Asia-Pacific and Latin America: China, India, Indonesia, Vietnam, Uzbekistan, Mexico, Malaysia, and Thailand representing over 840 million screening-age women and approximately 345,000 new cervical cancer cases annually. Screening coverage in these countries is very low and ranges from 9% in Indonesia to 40% in Mexico.

TruScreen holds regulatory approval in all eight target countries and already maintains active screening programmes or advanced pilots in each. China deploys TruScreen devices across 11 provinces with public health insurance reimbursement. Vietnam's Ho Chi Minh City Public Health Association has a signed MoU for a 260,000-woman screening programme across six public hospitals. Uzbekistan has an MoU with its Ministry of Health for national screening integration. This proposal provides the catalytic investment to transition these commercial pilots into nationally owned, publicly funded elimination services.

This proposal will screen over 650,000 women in 250+ health facilities during 4 years. It will establish TruScreen as a cornerstone of national cervical screening strategies across the 8 high-burden countries, building on existing regulatory approvals, MoUs, and in-country partnerships.

Of the US\$22.5M total budget, TruScreen share of funding would be US\$9.17M as lead implementer.

Tony Ho, chairman of TruScreen, said,

"TruScreen's point-of-care portable AI technology is purpose-built for the settings where cervical cancer kills most, where there are no laboratories, no pathologists, and no second visit. These three proposals to UNITAID represent our commitment to reaching the women who need screening most, in the communities where the burden is greatest."



“With 12 years of cervical screening in the field and over 40,000 women in clinical trials and publications, we are pleased that the TruScreen technology is recognised by WHO and UNITAID as a technology suitable for use in low and middle income countries. We are pleased to be able to collaborate with global and national NGOs and MoHs to put together this comprehensive response to UNITAID’S Call for Proposals.”

Our Partners

TruScreen Group Limited has assembled a consortium of nationally rooted, internationally recognised implementation partners for its two Africa proposals submitted to UNITAID's 2026 Call for Proposals on Cervical Cancer Elimination. Each partner brings a specific and complementary mandate spanning national HIV programme coordination, strengthening healthcare systems, primary care delivery, clinical research, and community health outreach.

National AIDS Council of Zimbabwe (NAC)

The National AIDS Council of Zimbabwe is the apex body responsible for coordinating Zimbabwe's national response to HIV and AIDS. NAC operates nationally, working directly with the Ministry of Health and Child Care to integrate cervical cancer screening into the national public health agenda. With HIV prevalence among Zimbabwean women remaining among the highest in Sub-Saharan Africa.

TruScreen and NAC have maintained a formal partnership since 2022, with NAC adopting TruScreen as its preferred cervical cancer screening technology and driving deployment across primary care centers nationwide. Under this partnership, more than 30,000 women have already been screened in Zimbabwe.

PATH

PATH is a global nonprofit organisation that drives transformative innovation in health to save lives. With more than four decades of experience in low- and middle-income countries, PATH has been one of the most influential organisations in advancing cervical cancer prevention globally, from pioneering affordable HPV-DNA testing and thermal ablation treatment to shaping national screening policies across Africa, Asia, and Latin America.

PATH brings deep expertise in strengthening health systems, supply chain management, regulatory navigation, and the design of scalable screening programmes. PATH provides programme design support, monitoring and evaluation frameworks, and the strategic linkages needed to drive long-term government ownership of screening services.

Solina Centre for International Development and Research (SCIDaR)

SCIDaR is a Nigerian nonprofit institution within the Solina Group, dedicated to accelerating positive health, social, and economic reforms through high-quality programme design, implementation, and capacity building. Operating across Nigeria and other African nations, SCIDaR combines rigorous scientific research with practical on-the-ground programme delivery, bridging the gap between global health evidence and local implementation reality.

It has established relationships with state and federal health authorities, has experience in training frontline health workers at scale, and has a track record in managing complex multi-site health programmes.

For personal use only



RedAid Nigeria

RedAid Nigeria is a Nigerian community health organisation with a strong presence in primary and community-level health service delivery. It focuses on bringing essential health services, including reproductive health, HIV care, and cancer awareness, directly to communities that sit furthest from formal healthcare infrastructure.

RedAid Nigeria plays an essential demand-generation and outreach role within the proposals. By mobilising communities, supporting health worker training, and facilitating access to screening services at the primary care level, RedAid Nigeria ensures that TruScreen's technology reaches the women who need it most, not only those who already seek care.

Baylor College of Medicine Children's Foundation Eswatini

The Baylor College of Medicine Children's Foundation Eswatini is the national leader in pediatric HIV/AIDS and tuberculosis care in one of the world's most heavily HIV-affected countries.

Baylor Foundation Eswatini has expanded its scope beyond pediatric HIV to encompass cancer screening, treatment, and education, including an established Education for Cancer Prevention and Treatment programme. Its clinical infrastructure, government relationships, and integrated HIV and cancer care model make it the natural delivery partner for TruScreen's programme in Eswatini.

Authorised by the Board for filing with the NZX/ASX.

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Jack Zhang
Media & Investor Relations
jack@sparkplus.org

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has



distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening.

DALTONbio's exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.

For personal use only